Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 11 Polycystic Ovary Syndrome 4 Prostatic Neoplasms 2 Heart Failure 2 Cardiotoxicity 2 Solid Tumors 1 Pediatric Brain Tumor 1 Pancreatic Neoplasms 1 Obesity 1 Lung Neoplasms 1 Inflammation 1 Hyperinsulinism 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Adenocarcinoma of Lung 1

Interventions

Paclitaxel 15 atezolizumab 11 Gemcitabine 11 Carboplatin 9 pembrolizumab 8 Docetaxel 8 Bevacizumab 8 Irinotecan 7 Injections 6 Cetuximab 6 Capecitabine 6 Sunitinib 5 Leucovorin 5 Fluorouracil 5 Cyclophosphamide 5 tocilizumab 4 pazopanib 4 olaparib 4 navitoclax 4 liposomal doxorubicin 4 Topotecan 4 Oxaliplatin 4 Nivolumab 4 Erlotinib Hydrochloride 4 temsirolimus 3 spartalizumab 3 lenvatinib 3 fludarabine 3 cobimetinib 3 Cisplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumors × dapagliflozin × Clear all

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡